Cell Signaling Technology Logo - Extra Large

PhosphoPlus® TAZ (Ser89) Antibody Duet #80074

Inquiry Info. # 80074

Please see our recommended alternatives.

    Product Information

    Product Description

    PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.

    Background

    TAZ is a transcriptional co-activator with a PDZ-binding motif that is regulated by its interaction with 14-3-3 proteins (1). TAZ shares homology with the WW domain of Yes-associated protein (YAP) (1). TAZ is proposed to modulate the switch between proliferation and differentiation of mesenchymal stem cells (MSC) via interaction with transcription factors Runx2 and PPARγ. This process is critical to normal tissue development and the prevention of tumor formation. Due to its role in determination of MSC fate, TAZ may have clinical relevance to several human diseases caused by an imbalance of MSC differentiation (2,3). TAZ is negatively regulated via phosphorylation by LATS1/2, core kinases in the Hippo signaling pathway that controls stem cell development, tissue growth and tumor development (4).
    Phosphorylation of TAZ at Ser89 functions to destabilize TAZ protein by promoting 14-3-3 binding, cytoplasmic sequestration, and proteasomal degradation, thereby reducing the ability of TAZ to co-activate transcription of downstream target genes. Mutation of Ser89 to alanine (S89A) yields a constitutively active form of TAZ; expression of TAZ (S89A) in breast cancer cells was shown to promote a cancer stem cell phenotype (5).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PhosphoPlus is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.